Publicaciones (224) Publicaciones de Bruno Paiva

2024

  1. A CD38/CD3xCD28 trispecific T-cell engager as a potentially active agent in multiple myeloma patients relapsed and/or refractory to anti-CD38 monoclonal antibodies

    British Journal of Haematology

  2. Biomarkers of Efficacy and Safety of the Academic BCMA-CART ARI0002h for the Treatment of Refractory Multiple Myeloma

    Clinical Cancer Research, Vol. 30, Núm. 10, pp. 2085-2096

  3. Curative Strategy for High-Risk Smoldering Myeloma: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) Followed by Transplant, KRd Consolidation, and Rd Maintenance

    Journal of Clinical Oncology, Vol. 42, Núm. 27, pp. 3247-3256

  4. Epigenetic-based differentiation therapy for Acute Myeloid Leukemia

    Nature Communications, Vol. 15, Núm. 1

  5. Hypocortisolemic ASIA: a vaccine- and chronic infection-induced syndrome behind the origin of long COVID and myalgic encephalomyelitis

    Frontiers in Immunology, Vol. 15

  6. Immune dysfunction prior to and during vaccination in multiple myeloma: a case study based on COVID-19

    Blood Cancer Journal, Vol. 14, Núm. 1

  7. Immunoparesis recovery in newly diagnosed transplant ineligible multiple myeloma patients, an independent prognostic factor that complements minimal residual disease

    Annals of Hematology

  8. Impact of treatment effect on MRD and PFS: an aggregate data analysis from randomized clinical trials in multiple myeloma

    Blood Advances

  9. Measurable residual disease by mass spectrometry and next-generation flow to assess treatment response in myeloma

    Blood

  10. Not so natural, not so killers

    Blood

  11. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma

    Blood, Vol. 143, Núm. 7, pp. 597-603

  12. RASping myeloma genomics

    Blood

  13. Randomized comparison between KTd and KRd induction therapy followed by maintenance therapy with K or observation in transplant-ineligible patients with newly diagnosed multiple myeloma

    American Journal of Hematology

  14. Recovery of uninvolved heavy/light chain pair immunoparesis in newly diagnosed transplant-eligible myeloma patients complements the prognostic value of minimal residual disease detection

    Haematologica, Vol. 109, Núm. 6, pp. 1909-1917

  15. Round Table Discussion on Optimal Clinical Trial Design in Precursor Multiple Myeloma

    Blood cancer discovery, Vol. 5, Núm. 3, pp. 146-152

  16. Selinexor, daratumumab, bortezomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma: results of the phase II, non-randomized, multicenter GEM-SELIBORDARA study

    Haematologica, Vol. 109, Núm. 7, pp. 2219-2228

  17. Serum mass spectrometry for treatment monitoring in patients with multiple myeloma receiving ARI0002h CAR T-cells

    British Journal of Haematology, Vol. 205, Núm. 4, pp. 1346-1355

  18. Targeting CD38 with isatuximab and a novel CD38/CD3×CD28 trispecific T-cell engager in older patients with acute myeloid leukemia

    Blood Advances

  19. The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression

    Blood cancer journal, Vol. 14, Núm. 1, pp. 74

2023

  1. Cobimetinib Alone and Plus Venetoclax With/Without Atezolizumab in Patients With Relapsed/Refractory Multiple Myeloma

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 23, Núm. 1, pp. e59-e70